Crizanlizumab (anti-P-selectin)
Crizanlizumab (anti-P-selectin) is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1) . Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3].
Product Specifications
CAS Number
1690318-25-2
UNSPSC
12352203
Target
P-selectin
Related Pathways
Immunology/Inflammation
Field of Research
Inflammation/Immunology
Smiles
[Crizanlizumab(anti-P-selectin)]
References & Citations
[1]Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020) . |[2]Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376 (5) :429-439.|[3]Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400043-500 1x 500 µL
P21 / WAF1 (WA-1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402848-500 1x 500 µL
Fibronectin (Fn-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740679-100 1x 100 µL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details